Navigation Links
Children's hay fever relieved by cellulose power without adverse effects
Date:6/28/2011

A cellulose powder has been used increasingly for many years against allergic rhinitis. Still, there has been a shortage of scientific evidence for its efficacy in seasonal allergic rhinitis (hay fever), particularly in children. Now, however, scientists from the Sahlgrenska Academy and the Department of Plant and Environmental Sciences at the University of Gothenburg have proven that the cellulose powder reduces symptoms of seasonal allergic rhinitis in children, without any adverse effects.

The powder is produced from pine trees and forms a barrier on the mucous membrane when puffed into the nose. This means that allergy causing substances are filtered out.

"The cellulose powder has no adverse effects, and this fact makes it a particularly attractive treatment for children. It is used increasingly in many countries, but there is until now no scientific study proving the efficacy of the cellulose powder in children during the pollen season", is the comment from Nils berg, associate professor at the Department of Pediatrics and consultant at the Queen Silvia Children's Hospital.

Therefore, a study was carried out at the Queen Silvia Children's Hospital in Gothenburg during the birch pollen season in spring 2009. The cellulose powder was compared with a placebo (a substance without any medical effect). Fifty-three children and adolescents aged 8-18 years with allergic reaction to pollen participated in the study, lasting for 4 weeks when they puffed the powder in the nose3 times daily. Every day they also were on an antihistamine tablet (the most common treatment of hay fever). Reminders and reporting of symptom scores were performed using SMS messaging on mobile phones.

Pollen occurrence was measured every day on the roof of the hospital, and the pollen counts subsequently were analysed in relation to the symptoms reported by the children. Further data for the study came from previously unpublished statistics of pollen levels collected for 31 years at the same location in Gothenburg, from 1979 to 2009.

"We showed that the nasal symptoms of the children were significantly reduced in those who used the cellulose powder. The best effect was obtained at low to moderate concentrations of pollen, corresponding to the predominating levels in the area during the 31-year period. Furthermore, no adverse effects of the cellulose powder were seen", Nils berg remarks. He concludes:

"The complete absence of adverse effects makes this treatment admirably suited to self-care, and particularly for the treatment of children. Controlled scientific studies such as the present also provide the healthcare system a basis for testing this product as a supplement to other treatments. It is often necessary to combine different agents, at least for parts of the pollen season."

HAY FEVER

Hay fever (seasonal allergic rhinitis) is caused by pollen allergy. It is the most common allergic condition, and approximately one third of Swedish young people is afflicted. Inhalation of the allergenic substances gives rise to symptoms of running nose, itching, sneezing and nasal congestion, often with symptoms also in the eyes and airways. Antihistamine tablets are the most common treatment, but cortisone nasal spray is also often used.


'/>"/>

Contact: Nils berg
nils.aberg@vgregion.gu.se
46-706-630-567
University of Gothenburg
Source:Eurekalert

Related medicine news :

1. Researcher at Childrens Hospital LA discovers way to overcome radiation resistance in leukemia
2. Parents Want Electronic Access to Their Childrens Docs: Survey
3. Researchers warn of fever from the forest
4. FDA Advisers Urge Infant Doses for Kids OTC Fever Relievers
5. FDA Panels to Weigh Dosing Labels for Kids OTC Fever Relievers
6. Fever During Pregnancy, Diabetes and Obesity May Raise Autism Risk
7. Kids Eczema, Hay Fever Linked to Allergic Asthma Later
8. Childhood eczema and hay fever leads to adult allergic asthma
9. Firstborn Kids Seem to Have More Food Allergies, Hay Fever
10. Shar-Pei Dogs Shed Light on Human Fever Syndromes
11. Kids Fevers May Not Always Need Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab Physical Therapy (PRPT) ... preferred physical therapy provider for Derby City CrossFit, effective immediately. , In addition ... quickly and effectively as possible, ProRehab’s sports physical therapists will work with athletes ...
(Date:4/25/2017)... ... April 25, 2017 , ... A ... student test score performance for the 2015-16 school year across Wisconsin’s public schools, ... Though it highlights important patterns in student test score performance, the report’s limited ...
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical ... partners to help with process innovation in drug formulation and manufacturing. CoreRx ... with state-of-the-art analytical equipment in support of their development and manufacturing goals. ...
(Date:4/25/2017)... ... ... MD is committed to providing the highest quality of spine care to all his patients. ... all my patients to alleviate possible future issues. I am pleased to have you as ... my trained staff will assist you in any way possible.” , Dr. Saad Chaudhary is ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... healthcare products, is introducing Flexadin UCII, part of the EQUISTRO line, at this ... joint health in horses at the immunologic level. , The scientifically-developed Flexadin UCII ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), ... the Urology, Uro/Gyn and Gynecology markets with innovative ... has joined the Company as Senior Vice President, ... position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has joined ...
(Date:4/20/2017)... 2017 Research and Markets has announced the ... by Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics ... ... will rise from USD 20 Billion in 2015 to around USD ... Technologies - Innovation Driven by Rapidly Expanding Injectables Market and Increasing ...
(Date:4/20/2017)... Eyevensys, a private biotechnology company ... expression technology that enables the safe, local, sustained production ... wide range of ophthalmic diseases, announces it has received ... Agency (MHRA) to advance its technology into clinical development. ... The EyeCET ...
Breaking Medicine Technology: